Nanotechnology: Players, products & prospects to 2018 (Volume II)

This major strategic analysis provides a detailed insight into the current and future market for nano-enabled drug delivery technology.

Additional Information

Nano-enabled Delivery

The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.

As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry’s need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.

The potential of future applications:
Tissue specific delivery - targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
Gene and vaccine delivery - non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
Controlled-release devices - design of new nanoporous, bioerodible membranes;
Increased biocompatibility - design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
Improved drug bioavailability and solubility - through the engineering of drugs and reagents by nanostructuring;
Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.

By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.

By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry’s delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.

This report is part of a major new 4-volume strategic analysis

Drug Delivery Technologies:
Players, Products & Prospects to 2018

Focusing on the sectors that are driving growth

VOLUME I
CONTROLLED- RELEASE

VOLUME II
NANOTECHNOLOGY

VOLUME III
NUCLEIC ACID DELIVERY

VOLUME IV
TARGETED DELIVERY

CONTENTS
EXECUTIVE SUMMARY & INTRODUCTION
- Overview of nanotechnology: past, present & future
- Nanotechnology: motivators & resistors
- Nanomedicines, formulations and product regeneration
NANOTECHNOLOGY IN DRUG DELIVERY
- Core nanotechnology used by the pharma industry
- Nano-engineered drugs
- Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle structures
- Current therapeutic applications of nanotechnology in drug delivery
- Leading brands that utilise nanotechnology delivery
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading nanotechnology drug delivery companies
- Strategic development & commercialisation partnerships and joint ventures
- Mergers, acquisitions, start-ups & spin offs
- Intellectual property
THE CURRENT & FUTURE MARKET
- Leading approved nano-enabled product sales 2009
- Companies developing nano-enabled product sales 2009
- Novel nano-enabled product sales 2018
- Global nano-enabled product sales 2018
COMPETITOR ANALYSIS
Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products using the delivery technology
- Competitor ratio analysis
Companies analysed
- Abraxis BioScience, Inc
- Access Pharmaceuticals, Inc
- AlphaRx Corporation
- ALZA Corporation
- Aphios Corporation
- Applied Pharma Research S.A.
- BioSante Pharmaceuticals, Inc
- Calando Pharmaceuticals, Inc
- Camurus A.B.
- Cerulean Pharma, Inc
- CytImmune Sciences, Inc
- Elan Corporation, Plc
- Enzon Pharmaceuticals, Inc.
- Gilead Sciences, Inc
- Introgen Therapeutics
- Mersana Therapeutics
- Nano Interface Technology
- Nano S Biotechnology GmbH
- NanoBio Corporation
- NanoBioMagnetics, Inc
- Nanobiotix, Inc
- NanoCarrier, Inc
- Nanotechnology Victoria, Ltd.
- NanoMaterials Technology
- Nanotherapeutics, Inc
- Novavax, Inc.
- SkyePharma, Plc
- Spherics Pharmaceuticals, Inc
- Starpharma Holdings, Ltd
APPENDICIES
- Nanotechnology approved drug sales 2008-2018
- Nanotechnology developmental drug sales 2008-2018
- Key nanotechnology delivery companies by 2018

Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.

In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:

Proprietary delivery technology
Applications of the delivery technology within the pharmaceutical industry
Management/technical expertise of the delivery specialist
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology

We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.

Multi-point evaluation and scoring assessment Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:

The technology
Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
The application of the technology within a number of therapy areas
Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
The current status of the technology in clinical development or following approval
Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products.
Competition within the technology arena
Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.
The drug delivery specialist’s expertise
Number of drug delivery systems in development, strategic alliances, financial position, marketing presence.
The product portfolio
Drug delivery systems under evaluation, products in development, commercialisation/development partnerships.
Potential drug sales
Based on key events such as market, competition, patent expiry, time of entry into the market.

About the Author
Dr Cheryl Barton is a highly regarded independent consultant with over 16 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer’s disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a senior equity analyst where she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.